Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 - March 31, 2021
Message from the CEO
IBT is conducting a phase III-study ( The Connection Study ) which is the last phase of the clinical development program with the pharmaceutical candidate IBP-9414 containing
Lactobacillus reuteri as active substance. The active substance is a human bacterial strain found naturally in breast milk. The objective of the study is to show that the active substance can prevent necrotizing enterocolitis (NEC) and improve sustained feeding tolerance.
The medical need of a well-functioning digestion system is very high in premature infants and it is our expectation that IBT s pharmaceutical candidate IBP-9414 may improve gut motility in nutritional uptake, and simultaneously also reduce the risk for several complications such as NEC.
Stockholm, Sweden - Sinch AB (publ) - XSTO: SINCH The total number of shares and votes in Sinch AB (publ), reg. no 556882-8908, ("Sinch") has changed during the month of April consequent upon the issue
DGAP-News: Swedish Electromagnet Invest AB (Publ): Annual Financial Report
Swedish Electromagnet Invest AB (Publ): Annual Financial Report
30.04.2021 / 12:00
Swedish Electromagnet Invest AB (publ)
Corp. Id. No 559153-6510
for the financial year
as PDF
http://www.rns-pdf.londonstockexchange.com/rns/2254X 1-2021-4-30.pdf
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
On December 18, 2020, the shares in Offentliga Hus i Norden AB (publ) (the
"Company") were given observation status on the grounds that
Samhällsbyggnadsbolaget i Norden AB ("SBB") had disclosed its intention
Annual Report English 2020 Zinzino AB (publ)
STOCKHOLM, April 28, 2021 /PRNewswire/
Zinzino (publ) announces that the Annual Report for 2020 is now published in Swedish at the company s website, zinzino.com. An English version will be published within 45 days.
Zinzino will hold the Annual General Meeting on Thursday May 20th, 2021. Taking into account the health of both the shareholders and the company representatives as well as ongoing efforts to limit the spread of infection, the Annual General Meeting will be held without the possibility of physical participation.
Shareholders exercise their voting rights at the Annual General Meeting only by prior postal voting in accordance with section 22 of the Temporary Exemptions Act to facilitate the conduct of company and association meetings. For voting, a digital form is used which is available on the company s website: